Kenji Ota, MD, PhD
Associate Research ScientistDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Associate Research Scientist
Appointments
Immunobiology
Associate Research ScientistPrimary
Other Departments & Organizations
- All Institutions
- Immunobiology
Education & Training
- PhD
- Nagasaki University, Biomedical Science (2021)
- MD
- Kyushu University (2012)
Research
Copy Link
Overview
Public Health Interests
Biomarkers; COVID-19; Emerging Infectious Diseases; Immunology; Infectious Diseases; Microbiome; Respiratory Disease/Infections
ORCID
0000-0001-7180-0820- View Lab Website
Iwasaki
Research at a Glance
Publications Timeline
A big-picture view of Kenji Ota's research output by year.
38Publications
246Citations
Publications
Featured Publications
Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination
Ota K, Sakai H, Sasaki D, Mitsumoto-Kaseida F, Sakamoto K, Kosai K, Hasegawa H, Takazono T, Izumikawa K, Mukae H, Tun M, Morita K, Yanagihara K. Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination. Virus Research 2023, 339: 199294. PMID: 38056502, PMCID: PMC10749273, DOI: 10.1016/j.virusres.2023.199294.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSARS-CoV-2 vaccinesSARS-CoV-2Immune response to severe acute respiratory syndrome coronavirus 2Response to severe acute respiratory syndrome coronavirus 2Recognition antigenMucosal immune responsesMucosal immune systemFunction of IgAS1 proteinOral cavitySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2IgA responsesMucosal immunityRespiratory syndrome coronavirus 2Vaccine doseImmune responseSalivary IgAViral infectionIgG antibodiesImmune systemSyndrome coronavirus 2IgAImmunoglobulin GSaliva samplesThe evaluation of a rapid microfluidic immunofluorescence antigen test in detecting the infectiousness of COVID-19 patients
Ota K, Kodama H, Kawamoto Y, Sasaki D, Mitsumoto-Kaseida F, Sakamoto K, Kosai K, Hasegawa H, Takazono T, Izumikawa K, Mukae H, Tun M, Morita K, Yanagihara K. The evaluation of a rapid microfluidic immunofluorescence antigen test in detecting the infectiousness of COVID-19 patients. BMC Infectious Diseases 2023, 23: 823. PMID: 37996783, PMCID: PMC10668452, DOI: 10.1186/s12879-023-08821-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNegative predictive valueVirus cultureAg testTest-based strategyAntigen testPredictive valuePositive predictive valueOnset of symptomsMild COVID-19Quantitative RT-PCR testsPrevention of infectionFalse negative resultsNasopharyngeal swab samplesCOVID-19 patientsLateral flow antigen testsQuantitative RT-PCRRT-PCR testPatientsImmunofluorescence methodMethodsThis studyRT-PCRSwab samplesNegative resultsCOVID-19 infectiousnessInfectionSerological response to a third dose of SARS-CoV-2 vaccine according to previous infection history
Ota K, Murakami S, Ishihara K, Sasaki D, Usui T, Mitsumoto-Kaseida F, Sakamoto K, Kosai K, Hasegawa H, Takazono T, Furumoto A, Asoh N, Yoshimine H, Sawai T, Onizuka M, Makimoto N, Izumikawa K, Mukae H, Kohno S, Yanagihara K. Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history. Vaccine X 2023, 13: 100282. PMID: 36960104, PMCID: PMC10022459, DOI: 10.1016/j.jvacx.2023.100282.Peer-Reviewed Original ResearchAltmetricPerformance of the GeneSoC Rapid PCR System in Detection of SARS-CoV-2 from Saliva Specimens
Ota K, Kurahara R, Tsukamoto C, Kawamoto Y, Akamatsu N, Sasaki D, Mitsumoto-Kaseida F, Sakamoto K, Kosai K, Hasegawa H, Yamamoto K, Izumikawa K, Mukae H, Yanagihara K. Performance of the GeneSoC Rapid PCR System in Detection of SARS-CoV-2 from Saliva Specimens. Microbiology Spectrum 2023, 11: e03259-22. PMID: 36779750, PMCID: PMC10101093, DOI: 10.1128/spectrum.03259-22.Peer-Reviewed Original ResearchCitationsDetection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples
Ota K, Yanagihara K, Sasaki D, Kaku N, Uno N, Sakamoto K, Kosai K, Miyazaki T, Hasegawa H, Fujita A, Tashiro M, Tanaka T, Izumikawa K, Ariyoshi K, Mukae H, Yasuda J, Morita K, Kohno S. Detection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples. PLOS ONE 2021, 16: e0252964. PMID: 34111203, PMCID: PMC8191987, DOI: 10.1371/journal.pone.0252964.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNasopharyngeal swabsSaliva specimensSARS-CoV-2Mild COVID-19 patientsLate phaseViral load detectionDiagnosis of coronavirus diseasePhase of infectionCOVID-19 patientsQuantitative RT-PCRAcute respiratory syndrome-coronavirus-2Severe acute respiratory syndrome-coronavirus-2Late phase of infectionMild patientsNasopharyngeal samplesSwabsRT-PCRDetection of SARS-CoV-2SARS-CoV-2 detectionSalivaPositive rateViral copiesPatientsDiagnosisCoronavirus diseaseEfficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia
Ota K, Kaku N, Yanagihara K. Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia. Journal Of Infection And Chemotherapy 2020, 26: 1237-1243. PMID: 32868198, DOI: 10.1016/j.jiac.2020.07.002.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsCarbapenem-resistant Klebsiella pneumoniaeCarbapenem-resistant EnterobacteriaceaeBroncho-alveolar lavage fluidAmikacin combination therapyEfficacy of meropenemCombination therapyMouse modelNeutrophil countCarbapenem-resistant Klebsiella pneumoniae clinical isolatesCRKP pneumoniaSpread of carbapenem-resistant EnterobacteriaceaeCombination therapy of meropenemMouse model of pneumoniaProgression of lung inflammationCombination antimicrobial therapyCombination therapy groupLimited treatment optionsAlveolar neutrophil infiltrationModel of pneumoniaTrachea of BALB/c miceGlobal health problemAntimicrobial therapyClinical isolatesLung inflammationUntreated control group
2026
Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study)
Yamamoto K, Iwanaga N, Umemura A, Sawai T, Sumiyoshi M, Hashiguchi K, Mori Y, Ishii H, Futsuki Y, Kiyohara M, Ota K, Kosai K, Sasaki D, Takamatsu Y, Inoue S, Morita K, Tsutsui S, Ashizawa K, Takazono T, Sakamoto N, Hosogaya N, Tashiro M, Tanaka T, Izumikawa K, Yanagihara K, Mukae H. Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study). Therapeutic Advances In Infectious Disease 2026, 13: 20499361261431488. PMID: 41884792, PMCID: PMC13009641, DOI: 10.1177/20499361261431488.Peer-Reviewed Original ResearchAltmetricConceptsCOVID-19 pneumoniaMild COVID-19 pneumoniaGroup AJapan RegistryPrimary endpointFms-like tyrosine kinase 3 ligandInflammatory cytokinesJapan Registry of Clinical TrialsProgression to severe diseaseTumor necrosis factor (TNF)-aGranulocyte colony stimulating factorOpen-label trialRegistry of Clinical TrialsEfficacy of clarithromycinInterleukin (IL)-7Colony stimulating factorSerum inflammatory cytokinesMild COVID-19Fibroblast growth factor (FGF)-2Clarithromycin groupSecondary endpointsFlt3-LG-CSFLiver eventsTherapeutic optionsRapid Typing of Extended‐Spectrum β‐Lactamase (ESBL)‐ and Metallo‐β‐Lactamase (MBL)‐Producing Enterobacterales Using Fourier Transform Infrared (FT‐IR) Spectroscopy
Kawamoto Y, Kosai K, Murata M, Ota K, Mitsumoto‐Kaseida F, Kaku N, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K. Rapid Typing of Extended‐Spectrum β‐Lactamase (ESBL)‐ and Metallo‐β‐Lactamase (MBL)‐Producing Enterobacterales Using Fourier Transform Infrared (FT‐IR) Spectroscopy. MicrobiologyOpen 2026, 15: e70218. PMID: 41627971, PMCID: PMC12863417, DOI: 10.1002/mbo3.70218.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsWhole-genome single-nucleotide polymorphismPulsed-field gel electrophoresisWhole-genome single-nucleotide polymorphism analysisMultilocus sequence typingExtended-spectrum b-lactamasesIR BiotyperMetallo-b-lactamasesB-lactamaseESBL-producing K. pneumoniae strainsSingle-nucleotide polymorphismsSequence typingClinical isolatesComplex isolatesGel electrophoresisBacterial strainsExtended-spectrumClonal similarityBiotypesEnterobacteralesOutbreak investigationStrainIsolatesAdjusted Rand IndexESBLElectrophoresis
2025
Efficacy of cefiderocol in murine models of ventilator-associated pneumonia caused by carbapenem-resistant non-fermenting Gram-negative bacilli, with pharmacokinetic evaluation
Ota K, Kaku N, Mitsumoto-Kaseida F, Uno N, Kosai K, Takazono T, Hasegawa H, Sakamoto K, Morinaga Y, Izumikawa K, Mukae H, Mikamo H, Yanagihara K. Efficacy of cefiderocol in murine models of ventilator-associated pneumonia caused by carbapenem-resistant non-fermenting Gram-negative bacilli, with pharmacokinetic evaluation. Microbiology Spectrum 2025, 14: e02568-25. PMID: 41433406, PMCID: PMC12889036, DOI: 10.1128/spectrum.02568-25.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsVentilator-associated pneumoniaFT >Carbapenem-resistant EnNon-fermenting Gram-negative bacilliGram-negative bacilliEfficacy of cefiderocolMurine modelCR-AbBacterial loadSurvival rateMICs of cefiderocolCR-PAIntratracheal inoculationEndotracheal tube placementAmount of drug exposureNon-fermenting bacteriaNon-clinical studiesNeutropenic miceInoculation of bacterial suspensionClinical responseDosing regimenDosing regimensDrug exposureCefiderocolTreatment optionsEfficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19: A Multicenter, Double-Blinded, Randomized-Controlled Trial (PLATEAU Study)
Yamamoto K, Inoue T, Ikeda T, Sawai T, Nagayoshi Y, Hashiguchi K, Futsuki Y, Matsubara Y, Harada Y, Ashizawa N, Fukahori S, Iwanaga N, Takazono T, Kido T, Ishimoto H, Hosogaya N, Sakamoto N, Tashiro M, Tanaka T, Fukushima C, Jounai K, Tsuji R, Fujiwara D, Ota K, Kosai K, Furumoto A, Yanagihara K, Izumikawa K, Mukae H. Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19: A Multicenter, Double-Blinded, Randomized-Controlled Trial (PLATEAU Study). Infectious Diseases And Therapy 2025, 14: 2835-2851. PMID: 41138036, PMCID: PMC12602773, DOI: 10.1007/s40121-025-01246-8.Peer-Reviewed Original ResearchAltmetricConceptsPlasmacytoid dendritic cellsLC-Plasma groupSARS-CoV-2 viral loadMild COVID-19Viral loadLC-PlasmaPrimary endpointSARS-CoV-2Lactococcus lactis strain PlasmaHuman plasmacytoid dendritic cellsResultsThe primary endpointMild adverse eventsProportion of patientsCough-variant asthmaStrain plasmaAntiviral immune responseRandomized-controlled trialsDouble-blindPlacebo groupTaste disturbanceSecondary endpointsDendritic cellsBetween-group differencesTaste disordersAdverse events
Academic Achievements & Community Involvement
Copy Link
Get In Touch
Copy Link
Contacts
Email
Academic Office Number